It's back: Eli Lilly's COVID-19 antibody combo makes its return after 2 months on the sidelines

In the two months since U.S. officials stopped distribution of Eli Lilly's COVID-19 antibody combo, rival Regeneron has taken hold of the market—and GlaxoSmithKline and Vir's newer version has gathered steam. But with a new green light, Eli Lilly's combo can try for a comeback.